XTL Biopharmaceuticals has brought on board Robertson Stephens International, the non-US arm of the US investment bank focused on growth companies, to work as financial adviser alongside WestLB Panmure.

XTL is domiciled in Israel, and has a London stock exchange listing. The share price took a battering around September last year, dropping to 32p, but is now up to 52.5p. The market capitalisation is about £70m.